Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizoaffective disorder~* Experiencing an acute exacerbation of psychotic symptoms~* A score of \>=4 on at least 3 of the following 7 PANSS items: Delusions (P1), Hallucinatory behavior (P3), Excitement (P4), Hostility (P7), Tension (G4), Uncooperativeness (G8), and Poor Impulse Control (G14)~* A score of \>=16 on YMRS and/or a score of \>=16 on the HAM-D-21~* Healthy based on physical examinations, electrocardiogram (ECG), laboratory tests, medical history, and vital signs measurements~Exclusion Criteria:~* A primary active mental illness diagnosis other than schizoaffective disorder~* Have attempted suicide within 12 months or are at imminent risk of suicide or violent behavior~* Subjects with first episode of psychosis~* Received electroconvulsive therapy in the past 3 months~* History of hypersensitivity to or intolerance of paliperidone, risperidone, or 20% Intralipid (placebo)~* Received long-acting antipsychotic medication within 2 injection cycles~* Received therapy with clozapine within 3 months~* A history of neuroleptic malignant syndrome~* Previous history of lack of response to antipsychotic medication~* Subjects receiving therapy with antidepressants or mood stabilizers that has been initiated and/or changed in dose \<30 days prior to screening~* Receiving therapy with carbamazepine~* Receiving therapy with monoamine oxidase inhibitors~* Pregnant, breast-feeding, or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
- 002 (Type: PLACEBO_COMPARATOR): Placebo monthly by i.m. injection for 15 months

Based on this trial design, predict the completion outcome and termination type (if applicable).